Humanized anti-lymphotoxin beta receptor antibodies

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S388100, C530S388220, C530S391700, C424S133100, C424S141100, C424S143100, C424S181100, C435S069600, C435S070210

Reexamination Certificate

active

07429645

ABSTRACT:
This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 2004/0058394 (2004-03-01), Garber et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0104971 (2006-05-01), Garber et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0280722 (2006-12-01), Browning et al.
patent: 2007/0154476 (2007-07-01), Browning et al.
patent: 0519596 (1992-12-01), None
patent: WO-91/09967 (1991-07-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO 9622788 (1996-08-01), None
patent: WO-99/38525 (1999-08-01), None
patent: WO 9958679 (1999-11-01), None
Campbell et al. Biology, 5th ed. p. 856, 1999.
Co et al. Nature, 351(6):501-502, Jun. 6, 1991.
William E. Paul, Fundamental immunology, 3rd ed., p. 242, 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, 1982.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
Foote et al. Journal of Molecular Biology, 224(2):487-499, 1992.
Alderson, Mark R. et al., “Regulation of apoptosis and T cell activation by Fas-specific mAb,”International Immunology, vol. 6(11):1799-1806 (1994).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry, vol. 267(4):2542-2547 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Bernstein, David I. et al., “Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development,”Antiviral Research, vol. 20:45-55 (1993).
Browning, Jeffrey L. et al., “Characterization of Surface Lymphotoxin Forms, Use of Specific Monoclonal Antibodies and Soluble Receptors,”The Journal of Immunology, vol. 154:33-46 (1995).
Browning, Jeffrey L. et al., “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Immunology, vol. 147(4):1230-1237 (1991).
Browning, Jeffrey L. et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,”Cell, vol. 72:847-856 (1993).
Browning, Jeffrey L. et al., “Signaling through the Lymphotoxin β Receptor Induces the Death of Some Adenocarcinoma Tumor Lines,”J. Exp. Med., vol. 183:867-878 (1996).
Browning, Jeffrey L. et al., “Signalling Through the Lymphotoxin-β Receptor in Conjunction with Interferon-γ Induces the Death of a Human Tumor Line,”The 9th International Congress of Immunology, No. 4582 (1995).
Browning, Jeffrey L. et al., “Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines,”The Journal of Immunology, vol. 143(6):1859-1867 (1989).
Couto, Joseph R. et al., “Humanization of KC4G3, an Anti-Human Carcinoma Antibody,”Hybridoma, vol. 13(3):215-219 (1994).
Crowe, Paul D. et al., “A Lymphotoxin-β-Specific Receptor,”Science, vol. 264:707-710 (1994).
Crowe, Paul D. et al., “Production of lymphotoxin (LTα) and a soluble dimeric form of its receptor using the baculovirus expression system,”Journal of Immunological Methods, vol. 168:79-89 (1994).
Dhein, Jens et al., “Induction of Apoptosis by Monoclonal Antibody Anti-Apo-1 Class Switch Variants is Dependent on Cross-Linking of APO-1 Cell Surface Antigens,”The Journal of Immunology, vol. 149(10):3166-3173 (1992).
Dighe, Anand S. et al., “Enhanced In Vivo Growth and Resistance to Rejection of Tumor Cells Expressing Dominant Negative IFNγ Receptors,”Immunity, vol. 1:447-456 (1994).
Düzgünes, Nejat et al., “Liposome Targeting to HIV-Infected Cells via Recombinant Soluble CD4 and CD4-IgG (Immunoadhesin),”Journal of Cellular Biochemistry, p. 77, No. Q514 (1992).
Eppstein, Deborah A. et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,”Proc. Natl. Acad. Sci. USA, vol. 82:3688-3692 (1985).
Fukushima, Keiko et al., “N-Linked Sugar Chain Structure of Recombinant Human Lymphotoxin Produced by CHO Cells: The Functional Role of Carbohydrate as to its Lectin-like Character and Clearance Velocity,”Archives of Biochemistry and Biophysics,vol. 304(1):144-153 (1993).
Havell, Edward A. et al., “The Antitumor Function of Tumor Necrosis Factor (TNF), I. Therapeutic Action of TNF against as Established Murine Sarcoma Is Indirect, Immunologically Dependent, and Limited by Severe Toxicity,”J. Exp. Med., vol. 167:1067-1085 (1988).
He, Xiaozhong et al., “General Introduction to Modern Biological Technique,”Publishing House of Beijing Normal University, 1st Edition, pp. 254-256 (1.8.3 &1.8.4).
Hipp, Jason D. et al., “Cancer Vaccines: An Update,” In Vivo, vol. 14:571-585 (2000).
Hwang, Karl J. et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study,”Proc. Natl. Acad. Sci. USA, vol. 77(7):4030-4034 (1980).
Jain, Rakesh K., “Vascular and interstitial barriers to delivery of therapeutic agents in tumors,”Cancer and Metastasis Reviews, vol. 9:253-266 (1990).
Johne, Berit et al., “Epitope mapping and binding kinetics of monoclonal antibodies studied by real time biospecific interaction analysis using surface plasmon resonance,”Journal of Immunological Methods, vol. 160:191-198 (1993).
Jurásková, Vera et al., “Interferon inducer, polyriboguanylic—polyribocytidylic acid, inhibits experimental hepatic metastases in mice,”European Journal of Pharmacology, vol. 221:107-111 (1992).
Kawabe, Tsutomu et al., “The Immune Responses in CD40-Deficient Mice: Impaired Immunoglobulin Class Switching and Germinal Center Formation,”Immunity, vol. 1:167-178 (1994).
Kolanus, Waldemar et al., “T Cell Activation by Clustered Tyrosine Kinases,”Cell, vol. 74:171-183 (1993).
Kolbinger, Frank et al., “Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies,”Protein Engineering, vol. 6(8):971-980 (1993).
Kopp, William C. et al., “Immunomodulatory Effects of Interferon-γ in Patients with Metastatic Malignant Melanoma,”Journal of Immunotherapy, vol. 13(3):181-190 (1993).
Lane, Peter et al., “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes,”Eur. J. Immunol., vol. 22:2573-2578 (1992).
Langer, Robert et al., “Biocompatibility of polymeric delivery systems for macromolecules,”Journal of Biomedical Materials Research, vol. 15:267-277 (1981).
Langer, Robert, “Controlled released of macromolecules,&#

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Humanized anti-lymphotoxin beta receptor antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanized anti-lymphotoxin beta receptor antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-lymphotoxin beta receptor antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3980930

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.